B-intervention	0	6	Manual
I-intervention	7	12	lymph
I-intervention	13	21	drainage
O	22	25	may
O	26	29	not
O	30	34	have
O	35	36	a
O	37	47	preventive
O	48	54	effect
O	55	57	on
O	58	61	the
O	62	73	development
O	74	76	of
O	77	83	breast
O	84	90	cancer
O	90	91	-
O	91	98	related
B-condition	99	110	lymphoedema
O	111	113	in
O	114	117	the
O	118	122	long
O	123	127	term
O	127	128	:
O	129	130	a
O	131	141	randomised
O	142	147	trial
O	147	148	.

O	149	153	What
O	154	157	are
O	158	161	the
O	162	167	short
O	167	168	-
O	168	172	term
O	173	176	and
O	177	181	long
O	181	182	-
O	182	186	term
O	187	197	preventive
O	198	205	effects
O	206	208	of
O	209	215	manual
O	216	221	lymph
O	222	230	drainage
O	231	232	(
O	232	235	MLD
O	235	236	)
O	236	237	,
O	238	242	when
O	243	247	used
O	248	250	in
O	251	259	addition
O	260	262	to
O	263	274	information
O	275	278	and
O	279	287	exercise
O	288	295	therapy
O	295	296	,
O	297	299	on
O	300	303	the
O	304	315	development
O	316	318	of
O	319	330	lymphoedema
O	331	336	after
O	337	345	axillary
O	346	356	dissection
O	357	360	for
O	361	367	breast
O	368	374	cancer
O	374	375	?

O	376	386	Randomised
O	387	397	controlled
O	398	403	trial
O	404	408	with
O	409	418	concealed
O	419	429	allocation
O	429	430	,
O	431	438	blinded
O	439	448	assessors
O	449	452	and
O	453	462	intention
O	462	463	-
O	463	465	to
O	465	466	-
O	466	471	treat
O	472	480	analysis
O	480	481	.

B-eligibility	482	488	Adults
I-eligibility	489	499	undergoing
I-eligibility	500	510	unilateral
I-eligibility	511	521	dissection
I-eligibility	522	525	for
I-eligibility	526	532	breast
I-eligibility	533	539	cancer
O	540	544	were
O	545	554	recruited
O	554	555	,
O	556	560	with
B-intervention-participants	561	563	79
O	564	573	allocated
O	574	576	to
O	577	580	the
O	581	593	experimental
O	594	599	group
O	600	603	and
B-control-participants	604	606	81
O	607	609	to
O	610	613	the
B-control	614	621	control
I-control	622	627	group
O	627	628	.

O	629	632	The
O	633	645	experimental
O	646	651	group
O	652	660	received
O	661	671	guidelines
O	672	677	about
O	678	688	prevention
O	689	691	of
O	692	703	lymphoedema
O	703	704	,
O	705	713	exercise
O	714	721	therapy
O	722	725	and
O	726	729	MLD
O	729	730	.

O	731	734	The
O	735	742	control
O	743	748	group
O	749	757	received
O	758	761	the
O	762	766	same
O	767	777	guidelines
O	778	781	and
O	782	790	exercise
O	791	798	therapy
O	798	799	,
O	800	803	but
O	804	806	no
O	807	810	MLD
O	810	811	.

O	812	815	The
O	816	829	interventions
O	830	832	in
O	833	837	both
O	838	844	groups
O	845	849	were
O	850	859	delivered
O	860	863	for
O	864	865	6
O	866	872	months
O	872	873	.

O	874	877	The
O	878	885	primary
O	886	893	outcome
O	894	897	was
B-outcome-Measure	898	908	cumulative
I-outcome-Measure	909	918	incidence
I-outcome-Measure	919	921	of
I-outcome-Measure	922	925	arm
I-outcome-Measure	926	937	lymphoedema
O	938	945	defined
O	946	948	in
O	949	953	four
O	954	958	ways
O	959	960	(
O	960	961	≥
O	961	966	200ml
O	966	967	,
O	967	968	≥
O	968	971	2cm
O	971	972	,
O	972	973	≥
O	973	974	5
O	974	975	%
O	975	976	,
O	977	980	and
O	980	981	≥
O	981	983	10
O	983	984	%
O	985	993	increase
O	993	994	)
O	994	995	,
O	996	1001	which
O	1002	1011	represent
O	1012	1015	the
O	1016	1026	difference
O	1027	1029	in
O	1030	1033	arm
O	1034	1040	volume
O	1041	1043	or
O	1044	1057	circumference
O	1058	1065	between
O	1066	1069	the
O	1070	1078	affected
O	1079	1082	and
O	1083	1090	healthy
O	1091	1096	sides
O	1097	1105	compared
O	1106	1110	with
O	1111	1114	the
O	1115	1125	difference
O	1126	1132	before
O	1133	1140	surgery
O	1140	1141	.

O	1142	1151	Secondary
O	1152	1160	outcomes
O	1161	1169	included
B-outcome-Measure	1170	1175	point
I-outcome-Measure	1176	1186	prevalence
I-outcome-Measure	1187	1189	of
I-outcome-Measure	1190	1201	lymphoedema
O	1201	1202	,
B-outcome-Measure	1203	1209	change
I-outcome-Measure	1210	1212	in
I-outcome-Measure	1213	1216	arm
I-outcome-Measure	1217	1223	volume
I-outcome-Measure	1224	1234	difference
O	1234	1235	,
B-outcome-Measure	1236	1244	shoulder
I-outcome-Measure	1245	1250	range
I-outcome-Measure	1251	1253	of
I-outcome-Measure	1254	1262	movement
O	1262	1263	,
B-outcome-Measure	1264	1271	quality
I-outcome-Measure	1272	1274	of
I-outcome-Measure	1275	1279	life
O	1280	1283	and
B-outcome-Measure	1284	1292	function
O	1292	1293	.

B-outcome	1294	1303	Incidence
I-outcome	1304	1309	rates
O	1310	1314	were
O	1315	1325	comparable
O	1326	1333	between
O	1334	1346	experimental
O	1347	1350	and
O	1351	1358	control
O	1359	1365	groups
O	1366	1368	at
O	1369	1372	all
O	1373	1379	follow
O	1379	1380	-
O	1380	1382	up
O	1383	1395	measurements
O	1395	1396	.

O	1397	1402	Sixty
O	1403	1409	months
O	1410	1415	after
O	1416	1423	surgery
O	1423	1424	,
O	1425	1428	the
B-outcome	1429	1439	cumulative
I-outcome	1440	1449	incidence
I-outcome	1450	1454	rate
I-outcome	1455	1458	for
I-outcome	1459	1462	the
I-outcome	1462	1463	≥
I-outcome	1463	1468	200ml
I-outcome	1469	1479	definition
O	1480	1483	was
B-iv-bin-percent	1484	1486	35
I-iv-bin-percent	1486	1487	%
O	1488	1491	for
O	1492	1495	the
O	1496	1508	experimental
O	1509	1514	group
O	1515	1521	versus
B-cv-bin-percent	1522	1524	29
I-cv-bin-percent	1524	1525	%
O	1526	1529	for
O	1530	1533	the
O	1534	1541	control
O	1542	1547	group
O	1548	1549	(
O	1549	1551	RR
O	1552	1553	0
O	1553	1554	.
O	1554	1556	89
O	1556	1557	,
O	1558	1560	95
O	1560	1561	%
O	1562	1564	CI
O	1565	1566	0
O	1566	1567	.
O	1567	1569	51
O	1570	1572	to
O	1573	1574	1
O	1574	1575	.
O	1575	1577	54
O	1577	1578	,
O	1579	1580	p
O	1580	1581	=
O	1581	1582	0
O	1582	1583	.
O	1583	1585	45
O	1585	1586	)
O	1586	1587	;
B-outcome	1588	1591	for
I-outcome	1592	1595	the
I-outcome	1595	1596	≥
I-outcome	1596	1599	2cm
I-outcome	1600	1610	definition
B-iv-bin-percent	1611	1613	35
I-iv-bin-percent	1613	1614	%
O	1615	1621	versus
B-cv-bin-percent	1622	1624	38
I-cv-bin-percent	1624	1625	%
O	1626	1627	(
O	1627	1629	RR
O	1630	1631	0
O	1631	1632	.
O	1632	1634	93
O	1634	1635	,
O	1636	1638	95
O	1638	1639	%
O	1640	1642	CI
O	1643	1644	0
O	1644	1645	.
O	1645	1647	59
O	1648	1650	to
O	1651	1652	1
O	1652	1653	.
O	1653	1655	45
O	1655	1656	,
O	1657	1658	p
O	1658	1659	=
O	1659	1660	0
O	1660	1661	.
O	1661	1663	73
O	1663	1664	)
O	1664	1665	;
B-outcome	1666	1669	for
I-outcome	1670	1673	the
I-outcome	1673	1674	≥
I-outcome	1674	1675	5
I-outcome	1675	1676	%
I-outcome	1677	1687	definition
B-iv-bin-percent	1688	1690	68
I-iv-bin-percent	1690	1691	%
O	1692	1698	versus
B-cv-bin-percent	1699	1701	53
I-cv-bin-percent	1701	1702	%
O	1703	1704	(
O	1704	1706	RR
O	1707	1708	1
O	1708	1709	.
O	1709	1711	28
O	1711	1712	,
O	1713	1715	95
O	1715	1716	%
O	1717	1719	CI
O	1720	1721	0
O	1721	1722	.
O	1722	1724	97
O	1725	1727	to
O	1728	1729	1
O	1729	1730	.
O	1730	1732	69
O	1732	1733	,
O	1734	1735	p
O	1735	1736	=
O	1736	1737	0
O	1737	1738	.
O	1738	1740	08
O	1740	1741	)
O	1742	1745	and
B-outcome	1746	1749	for
I-outcome	1750	1753	the
I-outcome	1753	1754	≥
I-outcome	1754	1756	10
I-outcome	1756	1757	%
I-outcome	1758	1768	definition
B-iv-bin-percent	1769	1771	28
I-iv-bin-percent	1771	1772	%
O	1773	1779	versus
B-cv-bin-percent	1780	1782	24
I-cv-bin-percent	1782	1783	%
O	1784	1785	(
O	1785	1787	RR
O	1788	1789	1
O	1789	1790	.
O	1790	1792	18
O	1792	1793	,
O	1794	1796	95
O	1796	1797	%
O	1798	1800	CI
O	1801	1802	0
O	1802	1803	.
O	1803	1805	66
O	1806	1808	to
O	1809	1810	2
O	1810	1811	.
O	1811	1813	10
O	1813	1814	,
O	1815	1816	p
O	1816	1817	=
O	1817	1818	0
O	1818	1819	.
O	1819	1821	57
O	1821	1822	)
O	1822	1823	.

O	1824	1827	The
O	1828	1837	secondary
O	1838	1846	outcomes
O	1847	1851	were
O	1852	1862	comparable
O	1863	1870	between
O	1871	1874	the
O	1875	1881	groups
O	1882	1884	at
O	1885	1889	most
O	1890	1900	assessment
O	1901	1907	points
O	1907	1908	.

O	1909	1915	Manual
O	1916	1921	lymph
O	1922	1930	drainage
O	1931	1934	may
O	1935	1938	not
O	1939	1943	have
O	1944	1945	a
O	1946	1956	preventive
O	1957	1963	effect
O	1964	1966	on
O	1967	1970	the
O	1971	1982	development
O	1983	1985	of
B-outcome	1986	1992	breast
I-outcome	1993	1999	cancer
I-outcome	1999	2000	-
I-outcome	2000	2007	related
I-outcome	2008	2019	lymphoedema
O	2020	2022	in
O	2023	2026	the
O	2027	2032	short
O	2033	2036	and
O	2037	2041	long
O	2042	2046	term
O	2046	2047	.

B-location	2048	2059	Netherlands
O	2060	2065	Trial
O	2066	2074	Register
O	2075	2078	NTR
O	2079	2083	1055
O	2083	2084	.

O	2085	2086	[
O	2086	2094	Devoogdt
O	2095	2096	N
O	2096	2097	,
O	2098	2106	Geraerts
O	2107	2108	I
O	2108	2109	,
O	2110	2113	Van
O	2114	2120	Kampen
O	2121	2122	M
O	2122	2123	,
O	2124	2126	De
O	2127	2133	Vrieze
O	2134	2135	T
O	2135	2136	,
O	2137	2140	Vos
O	2141	2142	L
O	2142	2143	,
O	2144	2149	Neven
O	2150	2151	P
O	2151	2152	,
O	2153	2160	Vergote
O	2161	2162	I
O	2162	2163	,
O	2164	2175	Christiaens
O	2176	2177	M
O	2177	2178	-
O	2178	2179	R
O	2179	2180	,
O	2181	2187	Thomis
O	2188	2189	S
O	2189	2190	,
O	2191	2193	De
O	2194	2199	Groef
O	2200	2201	A
O	2202	2203	(
O	2203	2207	2018
O	2207	2208	)
O	2209	2215	Manual
O	2216	2221	lymph
O	2222	2230	drainage
O	2231	2234	may
O	2235	2238	not
O	2239	2243	have
O	2244	2245	a
O	2246	2256	preventive
O	2257	2263	effect
O	2264	2266	on
O	2267	2270	the
O	2271	2282	development
O	2283	2285	of
O	2286	2292	breast
O	2293	2299	cancer
O	2299	2300	-
O	2300	2307	related
O	2308	2319	lymphoedema
O	2320	2322	in
O	2323	2326	the
O	2327	2331	long
O	2332	2336	term
O	2336	2337	:
O	2338	2339	a
O	2340	2350	randomised
O	2351	2356	trial
O	2356	2357	.

O	2358	2365	Journal
O	2366	2368	of
O	2369	2382	Physiotherapy
O	2383	2385	64
O	2385	2386	:
O	2387	2390	245
O	2390	2391	-
O	2391	2394	254
O	2394	2395	]
O	2395	2396	.
